VMD Sciences Supports Community Veterinary Oncologist in Securing Novel Treatment for Dog with Inoperable Cancer
VMD Sciences, the global leader in veterinary regulatory pharmaceutical services, played a pivotal role in helping a community veterinarian access an experimental treatment for a dog whose life-threatening soft tissue sarcoma was deemed inoperable. This success story highlights the potential of utilizing legislated regulatory pathways in veterinary medicine, a burgeoning field that offers hope for animals with serious health conditions where no other options are available.
The treating veterinarian sought support from VMD Sciences for Chrono, a 10-year-old Tamaskan canine who had been diagnosed with an aggressive soft tissue sarcoma in the upper jaw. The tumor was deemed inoperable due to the size and location of the mass, and all approved treatment options had been exhausted. Desperate for a solution, Chrono’s team set their sights on a novel medication that had been approved for use in treating similar conditions abroad.
Through VMD Sciences’ expertise in the global regulatory framework and global drug access, the veterinarian was guided through the complex process of requesting permission from their country’s regulatory agencies to legally and compliantly import the medication for Chrono. This process is known as Expanded Access, a regulatory route which provides exceptions for the use of experimental and/or foreign approved treatments when no other viable options exist.
Expanded Access: A New Era in Veterinary Medicine
Government legislated regulatory pathways allow veterinarians to compliantly import treatments that have not yet been approved in their country, typically under compassionate use or emergency use provisions. While these unique regulatory approvals are already common in human medicine, their application in veterinary medicine is an exciting development that holds promise for the future of animal healthcare with VMD Sciences leading the way.
“Expanded Access policies are game changers for the veterinary field,” said Richard Falcha, President at VMD Sciences. “They provide a crucial, compliant pathway for animals with rare or hard-to-treat conditions to access potentially life-saving therapies. Our team’s expertise in navigating these rigorous regulatory and fulfilment processes ensures that the right treatments can reach the right animals at the right time.”
A Promising Breakthrough
On January 22nd, 2025, VMD Sciences' Global Regulatory Experts successfully helped the veterinarian secure approval for their request to import the medication specifically for treating Chrono’s sarcoma.
“VMD Sciences’ impact on the world is going to be unprecedented; not only can they bring existing treatments to our beloved animals...but this team makes it possible to push into new frontiers of medical discovery – something the world desperately needs,” stated Chrono’s owner, Blossom. “We need more of this fight, more refusal to accept limitations, and more fearless pursuit of progress when we live in an era of immense connection and knowledge.”
This case marks a milestone in the growing field of veterinary medicine. As science continues to evolve, pathways like Expanded Access offer new avenues for veterinarians to explore unique and promising global treatments.
"Without the unique global regulatory expertise and dedication of VMD Sciences, we would never have been able to access this treatment. Thanks to their help, I have opened a new door of possibilities for animals in my practice.” - Community Veterinary Oncologist
About VMD Sciences:
VMD Sciences accelerates the benefits of biomedical innovation for animals, veterinarians, and pet owners through scientific partnerships with global pharmaceutical and biotechnology industries. Through its Global Veterinary Network, VMD Sciences leverages Expanded Access Programs and Clinical Study Solutions to provide life-saving treatment options for animals across the globe.
Source: www.vmdsciences.com
Comments
Related Articles
Copyright © 2026 - All Rights Reserved
ISSN 2768-198X
List
Add
Please enter a comment